![]()
The Problem
Vaccines are heat-sensitive and must be kept refrigerated. The vaccine “cold chain” is the system of transporting and storing vaccines within the temperature range of 35°F (2°C) to 45°F (8°C). If exposed to temperatures too high or too low, the vaccine will spoil or denature and become inactive. Injecting a spoiled vaccine reduces the potency and leaves the patient susceptible to the vaccine-preventable disease. This strict vaccine refrigeration requirement contributes to the 25% liquid vaccine wastage rate estimated by the WHO. The wastage rate for 10-20 vaccine dose vials is even higher, at an astounding 50%. The process also hinders the delivery of vaccines to remote areas of the world where there is no electricity to operate refrigerators. Of the 26 million children in the world who are not vaccinated in the world, 68% live in countries with the weakest immunization structures caused by transportation difficulties. The World Health Organization summarizes the current vaccine supply chain in low to middle-income countries into 12 steps.
[this section redacted]
Customers and Market Opportunity
The vaccine market is one of the fastest and most stable growing markets. Demand will always exist and in fact, in the past years, has continued to increase with the rise of new vaccines. Vaccine transportation costs have been identified as one of the largest expenses for our target customer comprising up to 90% of total vaccine delivery costs. Our product is specifically committed to lowering these large expenses because of NanoShield’s ability to eliminate the costly cold chain.
[this section redacted] Customers Care About Our Solution
Our Solution
Nanoly’s core product is a chemical solution called NanoShield. [this section redacted] Competitive Analysis
[this section redacted] Social Value
Because of the high costs of delivering vaccines, UNICEF estimates that an additional US$1 billion in financing is necessary every year to meet international goals of improving immunizations access and reducing child mortality in the poorest nations.
Social Value Proposition
Nanoly will provide a vaccine storage solution in order to help reach those most in need and to reduce the wastage factor of vaccines.
[this section redacted]
The Bottom Line
Regulatory Hurdles
[this section redacted]
Intellectual Property
[this section redacted]
Timeline
[this section redacted]
Funding to Exit
Our estimated dollar amount needed to fully develop our product and integrate it into the global vaccine supply chain is $1.5 million. We are confident that our technology would be of high interest to the following pharmaceutical companies who we believe will invest in our technology and help us achieve financial sustainability: [this section redacted] 2011 was one of the most successful years for healthcare M&A activity since 2001. There has been an upward trend in pharmaceutical companies acquiring biosimilars. Biotechnology is identified as one of the highest M&A activity groups with a total of $32.7 billion in deals last year. This upward trend indicates that pharmaceuticals are willing and possess the capital to invest in new technologies.
Management Team
[this section redacted] Adviser Team
Use of Award Budget [this section redacted] Total: $50,000 --
Starting March 21st, vote for us on the Duke Start-Up Challenge Facebook Page! And be sure to join us for the Grand Finale on April 20th at 7:30pm ET in Geneen Auditorium at the Fuqua School of Business, or live on Duke's Ustream Channel. RSVP for the event on Facebook
|